Biotech Values

[drbio45]

TGTX ($4.84, -10%) still selling off. Comments?


IF you listened to the Infinity webcast at the DB conference the analyst was focused on combo studies and the fact that infi doesn't own a second drug to go along with their PI3K inhibitor.

the reason I find that interesting is because the only company working in the space that owns a combo is TGTX.

pcyc, gilead, roche and abbott, do not have a combo.